PT  - JOURNAL ARTICLE
AU  - Wolfgang P. Fendler
AU  - Kambiz Rahbar
AU  - Ken Herrmann
AU  - Clemens Kratochwil
AU  - Matthias Eiber
TI  - <sup>177</sup>Lu-PSMA Radioligand Therapy for Prostate Cancer
AID  - 10.2967/jnumed.117.191023
DP  - 2017 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1196--1200
VI  - 58
IP  - 8
4099  - http://jnm.snmjournals.org/content/58/8/1196.short
4100  - http://jnm.snmjournals.org/content/58/8/1196.full
SO  - J Nucl Med2017 Aug 01; 58
AB  - 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.